Loading...
LGG-43. CLINICAL EXPERIENCE OF BRAF AND MEK INHIBITOR THERAPY IN PAEDIATRIC GLIOMA
INTRODUCTION: MAPK pathway activation is a druggable target and characteristic of paediatric low-grade(pLGG) and also found in high-grade glioma(pHGG), typically resulting from BRAFV600E/BRAF-fusion/NF1 mutations. METHODS: A retrospective cohort study of 23 patients, who received BRAF inhibitor mono...
Na minha lista:
| Udgivet i: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6012654/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.384 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|